Crossover Evolution: The Evolving Role of the Crossover Financing Round

The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became apparent. The prevailing financial...

2021 Q1 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q1 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...

Locust Walk 2020 Year End Report

Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2020 Year End Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...

Q3 Report: Global Trends in Biopharma Transactions

Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our Q3 2020 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape.   ...

Biopharma’s COVID Capital Comeback – A Whitepaper

What a difference a few months can make – especially during a pandemic. Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big...